Medicinal Cannabis Access in Victoria: A Regulatory Overview

Around 350,000 Australians have now been approved for medicinal cannabis through federal access pathways , a number the TGA's own published data confirmed had crossed that threshold by late 2024. Victoria is one of the largest patient populations in that figure. And yet, when I talk to people who've just been referred to a prescriber for the first time, most of them still have no clear picture of what they're actually dealing with legally. They reckon it's "legal now" and leave it at that. That's true, sort of. But the detail matters.

I've spent a lot of time reading the Poisons Standard , genuinely, not as a metaphor , and the Victorian picture is worth setting out clearly. Laws do change, so treat this as a structural overview rather than the final word on any current approval process. Always verify current requirements with the TGA and the Victorian Department of Health directly.

The federal layer: scheduling and the TGA

Before anything state-level makes sense, you need to understand that medicinal cannabis in Australia is primarily a federal regulatory matter. The Therapeutic Goods Administration controls what's scheduled, what's listed or registered on the Australian Register of Therapeutic Goods (ARTG), and how products can be lawfully supplied.

Most medicinal cannabis products in Australia are not fully registered on the ARTG in the way a standard prescription medicine would be. The overwhelming majority of approvals flow through either the Special Access Scheme (SAS) or the Authorised Prescriber pathway. Under SAS Category B; the most commonly used route, a medical practitioner applies to the TGA on behalf of a specific patient for a specific unapproved product. The Authorised Prescriber pathway allows an approved clinician to prescribe to a class of patients without individual TGA approval for each one, which tends to streamline repeat access.

Where a product sits in the scheduling framework shapes how it's handled at the dispensing end. Products containing cannabidiol (CBD) above certain concentrations are listed as Schedule 4 (prescription only) under the Poisons Standard. Products containing tetrahydrocannabinol (THC), or combinations of THC and CBD above the S4 thresholds; sit as Schedule 8 controlled drugs. That S8 designation has direct implications for Victorian prescribers and pharmacies, which I'll come to.

How Victoria layers on top

Victoria administers Schedule 8 substances through the Drugs, Poisons and Controlled Substances Act 1981 (Vic) and its associated regulations. This is the piece of legislation most Victorian prescribers bump up against in practice.

For any Schedule 8 medicinal cannabis product, Victorian prescribers must hold a current Victorian S8 permit, issued by the Victorian Department of Health, before they can prescribe. This is separate from and in addition to TGA approval under SAS or the Authorised Prescriber pathway. In other words, a doctor can have TGA approval for a patient and still not be able to lawfully prescribe in Victoria without the state permit sitting alongside it.

There are some permit exemptions for certain short-duration or specific-circumstance prescriptions, but the default rule is: permit required. The Department of Health's permit application process involves clinical justification, and permits are typically condition-specific. This is, honestly, one of the more administratively burdensome parts of the Victorian picture compared to some other states; and it's a point of genuine friction that patient groups have raised over the years. Whether that friction is proportionate is a policy debate I'll leave to others, but it's real.

What gets prescribed: a brief note on product types

Victorian patients accessing medicinal cannabis through these pathways may encounter products that vary significantly in their cannabinoid composition. Some are predominantly CBD-based; others contain meaningful proportions of THC; many are formulated as combinations. The terminology around product types, full-spectrum, broad-spectrum, and isolate, describes how much of the original plant's chemical profile has been retained or removed during processing.

Beyond THC and CBD, there is growing research interest in minor cannabinoids such as cannabigerol (CBG) and how the broader chemical composition of a product; including terpenes, may influence its profile. None of that is settled science at the level that changes how these products are scheduled or accessed. I'd be cautious about reading too much into early-stage minor-cannabinoid research as it applies to clinical use.

All legally supplied medicinal cannabis products in Australia must meet Good Manufacturing Practice (GMP) standards, whether manufactured domestically or imported. That's a federal requirement enforced through the TGA, and it's non-negotiable for any product used in the access pathways.

Dispensing: pharmacy and supply chain

Once a Victorian patient has both TGA approval and a valid S8 permit covering their prescriber, the prescription is filled at a pharmacy. Not all pharmacies stock or dispense medicinal cannabis, it requires specific handling, record-keeping, and storage arrangements consistent with Schedule 8 obligations under Victorian law. Some patients in regional Victoria have found this a genuine access issue; the supply chain hasn't expanded uniformly across the state.

Pharmacies that do dispense S8 medicinal cannabis must maintain the same controlled-drug registers and reporting they apply to other S8 substances. There's no shortcut around this. I was reading a consultation submission from the Pharmacy Guild on exactly this point last winter, while I was somewhere near the Captain's Flat Road on a long Saturday ride; the kind of thing that sounds odd until you admit that's genuinely when you catch up on reading. Anyway. The dispensing obligations are consistent, and they apply equally regardless of how the product is formulated.

Driving and impairment: a separate but connected issue

This deserves its own paragraph because it catches people out. Victoria's Road Safety Act 1986 and the Road Safety (Drivers) Regulations make no therapeutic exception for medicinal cannabis when it comes to roadside drug testing. Testing detects the presence of THC, not impairment. A lawful patient with a valid prescription can still be charged with driving with a prescribed concentration of drugs if THC is detected in an oral fluid test.

This is a distinct legal matter from the question of whether someone's prescription is valid. The two systems don't speak to each other in a way that protects a patient at a RBT stop. Some advocacy groups have pushed hard for a medicinal cannabis defence equivalent to what exists for some other jurisdictions, and there have been parliamentary inquiries into this in Victoria. As of the time of writing, no such defence exists in Victorian law. Patients should be aware of this, and it's something a prescribing clinician should be discussing.

Accessing further information

If you're a patient trying to understand your own situation, the TGA's published guidance on the SAS and Authorised Prescriber scheme is the primary federal reference. For Victorian-specific requirements, permit processes, S8 obligations, and any updates to the Drugs, Poisons and Controlled Substances Regulations, the Victorian Department of Health is the authority. Neither of those sources is especially light reading, but they're accurate.

The endocannabinoid system; the biological framework these compounds interact with, is covered separately in our Endocannabinoid System glossary entry if you want background on the pharmacology side of things. For the regulatory side, the short version is: dual-layer approval (federal + state), S8 controls apply to THC-containing products in Victoria, permit requirements sit with the prescriber, and driving law operates independently of prescription status.

The framework isn't simple, but it is coherent once you see how the layers fit together. And it does change, so check current requirements before acting on anything here.

Sources

• Medicinal Cannabis Hub; Therapeutic Goods Administration (TGA)
• Medicinal Cannabis, Victorian Department of Health
• Drugs, Poisons and Controlled Substances Act 1981, Victorian Legislation
• Guidance on the use of medicinal cannabis in Australia: Patient information; TGA

, Marcus Hale, Regulatory researcher, TGA & access law